Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

272 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.
Slingluff CL Jr, Colella TA, Thompson L, Graham DD, Skipper JC, Caldwell J, Brinckerhoff L, Kittlesen DJ, Deacon DH, Oei C, Harthun NL, Huczko EL, Hunt DF, Darrow TL, Engelhard VH. Slingluff CL Jr, et al. Cancer Immunol Immunother. 2000 Mar;48(12):661-72. doi: 10.1007/s002620050015. Cancer Immunol Immunother. 2000. PMID: 10752474 Free PMC article.
Cancer of the male breast.
English JC 3rd, Middleton C, Patterson JW, Slingluff CL. English JC 3rd, et al. Among authors: slingluff cl. Int J Dermatol. 2000 Dec;39(12):881-6. doi: 10.1046/j.1365-4362.2000.00007.x. Int J Dermatol. 2000. PMID: 11168652 Review. No abstract available.
Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients.
Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Teates D, Neese P, Grosh WW, Petroni G, Engelhard VH, Slingluff CL Jr. Yamshchikov GV, et al. Among authors: slingluff cl jr. Int J Cancer. 2001 Jun 1;92(5):703-11. doi: 10.1002/1097-0215(20010601)92:5<703::aid-ijc1250>3.0.co;2-5. Int J Cancer. 2001. PMID: 11340576 Free article.
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
Slingluff CL Jr, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbitts S, Teates D, Neese PY, Grosh WW, Chianese-Bullock KA, Woodson EM, Wiernasz CJ, Merrill P, Gibson J, Ross M, Engelhard VH. Slingluff CL Jr, et al. J Clin Oncol. 2003 Nov 1;21(21):4016-26. doi: 10.1200/JCO.2003.10.005. J Clin Oncol. 2003. PMID: 14581425 Clinical Trial.
272 results